exv10w5






Exhibit 10.5









Eli Lilly and Company

Shareholder Value Award



This Shareholder Value Award has been granted for the period of January 1, 2010 through
December 31, 2012 by Eli Lilly and Company, an Indiana corporation with its principal offices in
Indianapolis, Indiana (“Lilly” or the “Company”), to Grantee.



Performance Levels










	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	No Payout	 	Level 1	 	Level 2	 	Level 3	 	Level 4	 	Level 5	 	Level 6
	 
	 	 	 	 	 	$	30.05	 	 	$	34.28	 	 	$	38.50	 	 	$	41.00	 	 	$	43.50	 	 	 	 	 
	Stock Price
	 	 	£ $30.04	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	—	 	 	 	3 $46.00	 
	 
	 	 	 	 	 	$	34.27	 	 	$	38.49	 	 	$	40.99	 	 	$	43.49	 	 	$	45.99	 	 	 	 	 
	% of Target
	 	 	0	%	 	 	40	%	 	 	60	%	 	 	80	%	 	 	100	%	 	 	120	%	 	 	140	%














 









 








Eli Lilly
and Company Shareholder Value Award 





Table of Contents




	 	 	 	 	 
	A. Recitals
	 	 	3	 
	B. Shareholder Value Award
	 	 	3	 
	Section 1. Statement of Award Period
	 	 	3	 
	Section 2. Number of Shares
	 	 	3	 
	Section 3. Computation of Final Stock Price
	 	 	3	 
	Section 4. Determination and Announcement of Award
	 	 	4	 
	Section 5. Committee Election to Pay Cash
	 	 	4	 
	Section 6. Issuance or Transfer of Performance Shares and Payment of Cash Award
	 	 	4	 
	Section 7. Consideration for Continued Employment Requirement
	 	 	4	 
	Section 8. Adjustments for Certain Employment Status Changes
	 	 	4	 
	Section 9. Notices, Payments, and Electronic Delivery and Participation
	 	 	5	 
	Section 10. Waiver
	 	 	6	 
	Section 11. Revocation or Modification
	 	 	6	 
	Section 12. Withholding Tax
	 	 	6	 
	Section 13. Section 409A Compliance
	 	 	7	 
	Section 14. Non-Transfer of Shareholder Value Award
	 	 	7	 
	Section 15. Severability and Section Headings
	 	 	7	 
	Section 16. Determinations by Committee
	 	 	7	 
	Section 17. Change in Control
	 	 	7	 
	Section 18. Nature of 2002 Plan & Shareholder Value Award
	 	 	9	 
	Section 19. Data Privacy Notice and Consent
	 	 	10	 
	Section 20. Effective Date
	 	 	11	 
	Section 21. Governing Law
	 	 	11	 
	Section 22. Language
	 	 	11	 
	Section 23. Appendix
	 	 	12	 











Page 2









 






Eli Lilly
and Company Shareholder Value Award 





	A.	 	Recitals
	 
	 	 	Under the 2002 LILLY STOCK PLAN (“2002 Plan”), the Compensation Committee (“Committee”)
has determined the form of this Shareholder Value Award and selected the Grantee, an Eligible
Employee of the Company, to receive a Shareholder Value Award for the Award Period January 1,
2010 through December 31, 2012. The applicable terms of the 2002 Plan are incorporated in this
Shareholder Value Award by reference, including the definitions of terms contained in the 2002
Plan. This award is granted under Section 6 of the 2002 Plan, “Performance Awards to Eligible
Employees,” and shall be considered a form of Performance Award for purposes of interpretation
and administration of the award under the 2002 Plan.
	 
	B.	 	Shareholder Value Award
	 
	 	 	Lilly grants to the Grantee the right to acquire Lilly Stock by issuance or transfer to
the Grantee of the Performance Shares to which he or she is entitled under this Shareholder
Value Award upon the following terms and conditions, including any special terms and conditions
set forth in the appendix for the Grantee’s country of residence, if any, as provided in
Section 23:
	 
	 	 	Section 1. Statement of Award Period
	 
	 	 	The Award Period shall begin January 1, 2010 and end December 31, 2012.
	 
	 	 	Section 2. Number of Shares
	 
	 	 	The number of Performance Shares for the Award Period shall be determined by the
Performance Share value as approved by the Grantee’s supervisor and a FAS123(R) accepted
financial model. Target shares are set at Level 4. The remaining columns of the table on the
first page of this Shareholder Value Award are multiples of the target shares as set forth in
the % of Target row and correspond to the applicable stock price, subject to adjustment as
provided below in this Section or in Section 8. Grantees may view their Shareholder Value
Award by logging on to the Merrill Lynch website at
http://benefits.ml.com after March 31 of
each grant year.
	 
	 	 	The number of Performance Shares for the Award Period and the final stock price as defined
below in Section 3 will be adjusted by the Committee under Section 4(b) of the 2002 Plan upon
the occurrence, prior to the effective date of the issuance or transfer of shares for payment,
of any subdivision or combination of shares of Lilly Stock, or a stock dividend, capital
reorganization, recapitalization, or consolidation or merger with Lilly as the surviving
corporation, or if additional shares or new or different shares or other securities of Lilly or
any other issuer are distributed with respect to the shares of Lilly Stock through a spin-off,
exchange offer, or other extraordinary distribution occurring prior to the effective date of
the issuance or transfer of shares for payment. A fractional share resulting from such adjustment shall in the discretion of the Committee either
be paid in cash or rounded.
	 
	 	 	Section 3. Computation of Final Stock Price
	 
	 	 	The Final Stock Price shall be computed in accordance with Section 16 and using the
following procedures:








Page 3









 





Eli Lilly
and Company Shareholder Value Award 





	 	a.	 	The closing price for Lilly Stock on the New York Stock Exchange for each
trading day during the last two calendar months of the Award Period will be
collected and recorded.
	 
	 	b.	 	The stock price used to determine the payout level will be the average of
the closing stock prices collected in subsection (a) above rounded to the nearest
cent.






	 	 	Section 4. Determination and Announcement of Award
	 
	 	 	After the Final Stock Price for the Award Period is announced, the Final Stock Price and
the resulting number of Performance Shares for Grantee (determined in accordance with Sections
2 and 8), together with the Committee’s election between cash and shares of Lilly Stock under
Section 5, shall be communicated to Grantee.
	 
	 	 	Section 5. Committee Election to Pay Cash
	 
	 	 	At any time prior to award payout, the Committee may, if it so elects, determine to pay
part or all of any Shareholder Value Award in cash in lieu of issuing or transferring
Performance Shares. The
amount of cash shall be based upon the fair market value of Lilly Stock on a valuation date to
be determined by the Committee.
	 
	 	 	Section 6. Issuance or Transfer of Performance Shares and Payment of Cash Award
	 
	 	 	Subject to the condition relating to withholding tax stated in Section 12, Lilly shall
issue or transfer to the Grantee any Performance Shares to be issued or transferred under
Section 4 and pay to the Grantee any cash determined to be payable under that section within a
sixty day period starting the day after the Award Period expiration and ending on the sixtieth
day after the Award Period expiration as stated in Section 1. Grantee shall have no rights as
a shareholder of Lilly with respect to the shares of Lilly Stock until the shares are issued or
transferred on the books of Lilly.
	 
	 	 	Section 7. Consideration for Continued Employment Requirement
	 
	 	 	This Shareholder Value Award is made in consideration of services rendered by the
Grantee to the Company during the entire Award Period. If the status of the Grantee as an
Eligible Employee, as defined in the 2002 Plan, terminates before the end of the Award Period
except as outlined in Section 8 (c), then all rights of the Grantee under this Shareholder
Value Award shall terminate with respect to the Award Period. The Company shall incur no
liability to Grantee under this Shareholder Value Award by terminating Grantee’s status as an
Eligible Employee whether by action with respect to Grantee individually, either with or
without cause, or by dissolution or liquidation of Lilly or merger or consolidation of Lilly
with a corporation in which Lilly is not the surviving corporation, or otherwise.
	 
	 	 	Section 8. Adjustments for Certain Employment Status Changes
	 
	 	 	The number of Performance Shares described in Section 2 is based on the assumption that
the Grantee is an employee in good standing throughout the entire Award Period. Unless
otherwise required by law, the number of Performance Shares shall be adjusted for changes in
employment status during the Award Period as follows:








Page 4









 





Eli Lilly
and Company Shareholder Value Award 




	 	a.	 	Leaves of Absence. The number of Performance Shares shall be
reduced proportionally for any portion of the total days in the Award Period
during which the Grantee is on an approved unpaid leave of absence longer than
ninety (90) days.
	 
	 	b.	 	Demotions and Disciplinary Actions. The Committee may, at its
discretion, reduce the number of Performance Shares, prorated according to time,
for any portion of the Award Period during which the Grantee has been (i) demoted
to a job classification below those considered by the Committee to be eligible for
Shareholder Value Awards, or (ii) subject to disciplinary action by the Company.
In the case of disciplinary action during the Award Period, the Committee may, at
its discretion, withhold payment of this Shareholder Value Award entirely.
	 
	 	c.	 	Retirement, death, disability or termination due to a plant closing or
reduction in workforce. In the event the Grantee’s employment is terminated
due to retirement as a retiree, death, disability, plant closing or reduction in
workforce (as defined below), the number of Performance Shares shall be reduced
proportionally for the portion of the total days during the Award Period in which
the Grantee was not an active employee. Any payment of Performance Shares that
have been reduced by operation of this Section 8.c. shall be paid following the
Award Period expiration as described in Section 6. A retiree is a person who is
(i) a retired employee under the Lilly Retirement Plan; (ii) a retired employee
under the retirement plan or program of a Lilly subsidiary; or (iii) a retired
employee under a retirement program specifically approved by the Committee. Plant
closing means the closing of a plant site or other corporate location that directly
results in termination of employment. Reduction in workforce means the elimination
of a work group, functional or business unit or other broadly applicable reduction in
job positions that directly results in termination of employment. The Committee will
be responsible for approving, in its discretion, what is classified as disability, a
plant closing, or a reduction in workforce.






	 	 	Section 9. Notices, Payments, and Electronic Delivery and Participation
	 
	 	 	Any notice to be given by the Grantee or Successor Grantee shall be in writing, and any
notice or payment shall be deemed to have been given or made only upon receipt thereof by the
Treasurer of
Lilly at Lilly Corporate Center, Indianapolis, Indiana 46285, U.S.A. Any notice or
communication by Lilly in writing shall be deemed to have been given in the case of the Grantee
if mailed or delivered to the Grantee at any address specified in writing to Lilly by the
Grantee and, in the case of any Successor Grantee, at the address specified in writing to Lilly
by the Successor Grantee. In addition, Lilly may, in its sole discretion, decide to deliver
any documents related to the Shareholder Value Award grant or future awards under the 2002 Plan
by electronic means or request the Grantee’s consent to participate in the 2002 Plan by
electronic means. By accepting this Shareholder Value Award, the Grantee hereby consents to
receive such documents by electronic delivery and agrees to
participate in the 2002 Plan through an on-line or electronic system established and maintained
by Lilly or another third party designated by Lilly.








Page 5









 





Eli Lilly
and Company Shareholder Value Award 




	 	 	Section 10. Waiver
	 
	 	 	The waiver by Lilly of any provision of this instrument at any time or for any purpose
shall not operate as or be construed to be a waiver of that provision or any other provision of
this instrument at any subsequent time or for any other purpose.
	 
	 	 	Section 11. Revocation or Modification
	 
	 	 	This Shareholder Value Award shall be irrevocable except that Lilly shall have the right
to revoke or modify this Shareholder Value Award under Section 13(e) of the 2002 Plan.
	 
	 	 	Section 12. Withholding Tax
	 
	 	 	Regardless of any action Lilly and/or the Grantee’s employer (the “Employer”) takes with
respect to any or all income tax (including federal, state, local and non-U.S. tax), social
insurance, payroll tax, payment on account or other tax-related withholding (“Tax Related
Items”), the Grantee acknowledges that the ultimate liability for all Tax Related Items legally
due by the Grantee is and remains the Grantee’s responsibility and that Lilly and the Employer
(a) make no representations or undertakings regarding the treatment of any Tax Related Items in
connection with any aspect of the Shareholder Value Award, including the grant of the
Shareholder Value Award, the transfer and issuance of any Performance Shares or the receipt of
any cash payment pursuant to this Shareholder
Value Award, the receipt of any dividends and the sale of any Performance Shares acquired
pursuant to this Shareholder Value Award; and (b) do not commit to structure the terms of the
grant or any aspect of the Shareholder Value Award to reduce or eliminate the Grantee’s
liability for Tax Related Items.
	 
	 	 	Prior to the applicable tax event, the Grantee shall pay, or make adequate arrangements
satisfactory to Lilly and/or the Employer to satisfy all Tax Related Items. In this regard,
the Grantee authorizes Lilly and/or the Employer to withhold all applicable Tax Related Items
legally payable by the Grantee from the Grantee’s wages or other cash compensation payable to
the Grantee by Lilly and/or the
Employer or from any cash payment received upon expiration of the Award Period in accordance
with Section 6. Alternatively, or in addition, if permissible under local law, the Grantee
authorizes Lilly and/or the Employer, at their discretion, to (i) withhold from the proceeds of
the sale of Performance Shares acquired pursuant to this Shareholder Value Award, (ii) arrange
for the sale of Performance Shares to be issued upon the expiration of the Award Period (at the
Grantee’s behalf and at the Grantee’s direction pursuant to this authorization), and/or (iii)
withhold in Performance Shares otherwise issuable to the Grantee pursuant to this Shareholder
Value Award, provided that Lilly and/or the Employer shall withhold only the number of
Performance Shares necessary to satisfy the minimum withholding amount (or such other amount
that, as determined by Lilly, will not
trigger unfavorable accounting). If the obligation for Tax Related Items is satisfied by
withholding Performance Shares as described in (iii) herein, the Grantee will be deemed to have
been issued the full number of Performance Shares to which he or she is entitled pursuant to
this Shareholder Value Award, notwithstanding that a number of Performance Shares are withheld
to satisfy the obligation for Tax Related Items. The Grantee shall pay to Lilly and/or the
Employer any amount of Tax Related Items that Lilly and/or the Employer may be required to
withhold as a result of any aspect of this Shareholder Value Award that cannot be satisfied by
the means previously described. Lilly may 








Page 6









 





Eli Lilly
and Company Shareholder Value Award 



	 	 	refuse to deliver Performance Shares or any cash
payment to the Grantee if the Grantee fails to comply with the Grantee’s obligation in
connection with the Tax Related Items as described herein.






	 	 	Section 13. Section 409A Compliance
	 
	 	 	To the extent applicable, it is intended that this Shareholder Value Award comply with the
requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended and the
Treasury Regulations and other guidance issued thereunder (“Section 409A”), and this
Shareholder Value Award shall be interpreted and applied by the Committee in a manner
consistent with this intent in order to avoid the imposition of any additional tax under
Section 409A. This Shareholder Value Award is subject to Section 13(k) of the 2002 Plan
concerning Section 409A.
	 
	 	 	Section 14. Non-Transfer of Shareholder Value Award
	 
	 	 	No right in or under this Shareholder Value Award is transferable except by operation of
law to a duly appointed guardian of the estate of Grantee or upon the death of the Grantee by
will or the applicable laws of descent and distribution and then only subject to the provisions
of Sections 7 and 8.
	 
	 	 	Section 15. Severability and Section Headings
	 
	 	 	If one or more of the provisions of this instrument shall be held invalid, illegal or
unenforceable in any respect, the validity, legality and enforceability of the remaining
provisions shall not in any way be affected or impaired thereby and the invalid, illegal or
unenforceable provisions shall be deemed null and void; however, to the extent permissible by
law, any provisions which could be deemed null
and void shall first be construed, interpreted or revised retroactively to permit this
instrument to be construed so as to foster the intent of this Shareholder Value Award and the
2002 Plan.
	 
	 	 	The section headings in this instrument are for convenience of reference only and shall not be
deemed a part of, or germane to, the interpretation or construction of this instrument.
	 
	 	 	Section 16. Determinations by Committee
	 
	 	 	Determinations by the Committee pursuant to any provision of the 2002 Plan, pursuant to
rules, regulations and procedures adopted by the Committee or pursuant to this instrument,
including without limitation the determination of the amount and method of computation of the
Stock Price,
whether to make an exception to the rule of Section 7, or adjustments under Section 2 or
Section 3, shall be final and binding on the Grantee and any Successor Grantee.
	 
	 	 	Section 17. Change in Control
	 
	 	 	The provisions of Section 12(a)(iii) of the 2002 Plan apply to this Shareholder Value
Award with the following modifications:






	 	a.	 	The only Change in Control event that shall result in a payment under
Section 12(a)(iii) of the 2002 Plan shall be consummation of a change in ownership
of the Company as defined in Section 12(b)(i) of the 2002 Plan (a “Transaction”).








Page 7









 





Eli Lilly
and Company Shareholder Value Award 




	 	b.	 	On the date of the consummation of such Transaction, the Grantee will be
paid an amount equal to the product of (a) the Grantee’s award opportunity for the
Shareholder Value Award based on the value of Lilly Stock established for the
consideration to be paid to holders of Lilly Stock in the Transaction, and (b) a
fraction, the numerator of which is the number of days that have elapsed since the
beginning of the Award Period to the date of the consummation of the Transaction
and the denominator of which is the total number of days in the Award Period. The
payment will be deemed to have been made immediately prior to the consummation of
the Transaction in order to allow the Performance Shares
paid to be deemed outstanding and eligible to receive the consideration being paid to
Lilly shareholders in the Transaction.








Page 8









 





Eli Lilly
and Company Shareholder Value Award 




	 	 	Section 18. Nature of 2002 Plan & Shareholder Value Award
	 
	 	 	In accepting this Shareholder Value Award, the Grantee acknowledges that:






	 	a.	 	the 2002 Plan is established voluntarily by Lilly, it is discretionary in
nature and may be modified, amended, suspended or terminated by Lilly at any time,
as provided in the 2002 Plan;
	 
	 	b.	 	the Shareholder Value Award is voluntary and occasional and does not create
any contractual or other right to receive future Shareholder Value Awards, or
benefits in lieu
of Shareholder Value Awards even if Shareholder Value Awards have been granted
repeatedly in the past;
	 
	 	c.	 	all decisions with respect to future grants of Shareholder Value Awards, if
any, will be at the sole discretion of Lilly;
	 
	 	d.	 	the Grantee’s participation in the 2002 Plan is voluntary;
	 
	 	e.	 	the Shareholder Value Award is an extraordinary item that does not
constitute compensation of any kind for services of any kind rendered to Lilly or
the Employer and which is outside the scope of the Grantee’s employment contract,
if any;
	 
	 	f.	 	the Shareholder Value Award is not part of normal or expected compensation
or salary for any purposes, including, but not limited to, calculation of any
severance, resignation, termination, redundancy, end of service payments, bonuses,
long-service awards, pension or welfare or retirement benefits or similar payments
and in no event should be
considered as compensation for, or relating in any way to, past services for Lilly or
the Employer;
	 
	 	g.	 	neither the Shareholder Value Award nor any provision of this instrument,
the 2002 Plan or the policies adopted pursuant to the 2002 Plan confer upon the
Grantee any right with respect to employment or continuation of current
employment, and in the event that the Grantee is not an employee of Lilly or any
subsidiary of Lilly, the Shareholder Value Award shall not be interpreted to form
an employment contract or relationship with Lilly or any subsidiary of Lilly;
	 
	 	h.	 	the future value of the underlying Performance Shares is unknown and cannot
be predicted with certainty;
	 
	 	i.	 	the value of any Performance Shares acquired upon expiration of the Award
Period may increase or decrease in value, even below the tax valuation price;
	 
	 	j.	 	no claim or entitlement to compensation or damages shall arise from
termination of the Shareholder Value Award or from any diminution in value of the
Shareholder Value Award
or Performance Shares acquired upon expiration of the Award Period resulting from
termination of the Grantee’s employment by Lilly or the Employer (for any reason








Page 9









 





Eli Lilly
and Company Shareholder Value Award 



	 	 	 	whatsoever and whether or not in breach of local labor laws) and the Grantee
irrevocably releases Lilly and the Employer from any such claim that may arise; if,
notwithstanding the foregoing, any such claim is found by a court of competent
jurisdiction to have arisen, then, by accepting this Shareholder Value Award, the
Grantee shall be deemed irrevocably to have waived his or her entitlement to pursue
such claim;
	 
	 	k.	 	in the event of termination of the Grantee’s employment (whether or not in
breach of local labor laws), the Grantee’s right to receive Performance Shares
upon expiration of the Award Period will terminate effective as of the date the
Grantee is no longer actively employed (unless one of the adjustments in Section 8
applies) and will not be extended by any notice period mandated under local law
(e.g., active employment would not include a period of “garden leave” or similar
period pursuant to local law); the Committee shall have the exclusive discretion
to determine when the Grantee is no longer actively employed for purposes of the
Shareholder Value Award;
	 
	 	l.	 	Lilly is not providing any tax, legal or financial advice, nor is Lilly
making any recommendations regarding the Grantee’s participation in the 2002 Plan,
or the Grantee’s acquisition or sale of the underlying Performance Shares; and
	 
	 	m.	 	the Grantee is hereby advised to consult with his or her own personal tax,
legal and financial advisors regarding the Grantee’s participation in the 2002
Plan before taking any action related to the 2002 Plan.






	 	 	Section 19. Data Privacy Notice and Consent
	 
	 	 	The Grantee hereby explicitly and unambiguously consents to the collection, use and
transfer, in electronic or other form, of the Grantee’s personal data as described in this
Shareholder Value Award
by and among, as applicable, the Employer, Lilly, its subsidiaries and its affiliates for the
exclusive purpose of implementing, administering and managing the Grantee’s participation in
the 2002 Plan.
	 
	 	 	The Grantee understands that Lilly may hold certain personal information about the Grantee,
including, but not limited to, the Grantee’s name, home address and telephone number, date of
birth, social insurance number or other identification number, salary, nationality, job title,
any shares of stock or directorships held in Lilly, details of all Shareholder Value Awards or
any other entitlement to shares awarded, canceled, vested, unvested or outstanding in the
Grantee’s favor, for the purpose of implementing, administering and managing the 2002 Plan
(“Data”). The Grantee understands that
Data may be transferred to any third parties assisting in the implementation, administration
and management of the 2002 Plan, that these recipients may be located in the Grantee’s country,
or elsewhere, and that the recipient’s country may have different data privacy laws and
protections than the Grantee’s country. The Grantee authorizes the recipients to receive,
possess, use, retain and transfer the Data, in electronic or other form, for the purposes of
implementing, administering and managing the Grantee’s participation in the 2002 Plan,
including any requisite transfer of such Data as may be required to a broker, escrow agent or
other third party with whom any shares received upon expiration of the Award Period may be
deposited. The Grantee understands that Data will be held only as long as is necessary to
implement, administer and manage the Grantee’s participation in








Page 10









 





Eli Lilly
and Company Shareholder Value Award 



	 	 	the 2002 Plan. The Grantee understands that the Grantee may, at any time, request an equity
award transaction statement, request any necessary amendments to Data or refuse or withdraw the
consents herein, in any case without cost, by contacting in writing the Grantee’s local human
resources representative. The Grantee understands that refusal or withdrawal of consent may
affect the Grantee’s ability to participate in the 2002 Plan. For more information on the
consequences of the Grantee’s refusal to consent or withdrawal of consent, the Grantee
understands that the Grantee may contact the Grantee’s local human resources representative.






	 	 	Section 20. Effective Date
	 
	 	 	The effective date of this instrument shall be the date of grant.
	 
	 	 	Section 21. Governing Law
	 
	 	 	The validity and construction of this Shareholder Value Award shall be governed by the
laws of the State of Indiana, U.S.A. without regard to laws that might cause other law to
govern under applicable principles of conflict of laws. For purposes of litigating any dispute
that arises under this Shareholder Value Award, the parties hereby submit to and consent to the
jurisdiction of the State of Indiana, and agree that such litigation shall be conducted in the
courts of Marion County, Indiana, or the federal courts for the United States for the Southern
District of Indiana, and no other courts, where this Shareholder Value Award is granted and/or
to be performed.
	 
	 	 	Section 22. Language
	 
	 	 	If the Grantee has received this instrument or any other document related to the 2002 Plan
translated into a language other than English and if the translated version is different than
the English version, the English version will control.








Page 11









 





Eli Lilly
and Company Shareholder Value Award 




	 	 	Section 23. Appendix
	 
	 	 	If the Grantee is a non-U.S. resident, his or her participation in the 2002 Plan and this
Shareholder Value Award will be subject to the special terms and conditions set forth in the
appendix for the Grantee’s country of residence, if any (“Appendix”). The Appendix constitutes
part of this instrument.




IN WITNESS WHEREOF, Lilly has caused this Shareholder Value Award to be executed and granted in
Indianapolis, Indiana, by its proper officer.




	 	 	 	 	 
	 	ELI LILLY AND COMPANY

 	 
	 	By:  	
 	 
	 	 	John Lechleiter 	 
	 	 	Chairman of the Board and

Chief Executive Officer 	 
	 






Page 12